BeOne Medicines AG (BEIGF) Price and Market Data

BeOne Medicines Ltd. is a holding company that, through its subsidiaries, operates as an oncology-focused biopharmaceutical business dedicated to the discovery and development of cancer treatments. Its portfolio includes BRUKINSA, a Bruton's tyrosine kinase (BTK) inhibitor, sonrotoclax, a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. BeOne Medicines operates in a single segment, pharmaceutical products, and derives most of its revenue from the sale of its biopharmaceutical products.